EcoDrugPlus

Janus Kinase 3

Ensembl ID : ENSPSNG00000003933
Gene Symbol: JAK3
1 Cross references
103 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSPSNG00000000276
Gene Symbol: KIT
3 Cross references
265 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSPSNG00000007396
Gene Symbol: KRAS
3 Cross references
201 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPSNG00000012181
Gene Symbol: LCK
1 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPSNG00000012016
Gene Symbol: LYN
3 Cross references
202 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSPSNG00000020856
Gene Symbol: MALT1
1 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSPSNG00000016943
Gene Symbol: MAPKAPK2
3 Cross references
233 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSPSNG00000007634
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSPSNG00000007285
Gene Symbol: MKNK1
3 Cross references
167 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSPSNG00000017526
Gene Symbol: MKNK2
3 Cross references
220 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSPSNG00000002164
Gene Symbol: MCL1
3 Cross references
238 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSPSNG00000004530
Gene Symbol: MDM2
3 Cross references
262 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).